Project Grant R01CA315210
Award Date 7/20/26
Completion Date 6/30/29
Dollars Obligated $663K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- The National Cancer Institute awarded the University of California, San Diego $663,998 on July 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct mechanistic research on targeting the Type I interferon pathway to improve cancer therapy efficacy. The research investigates how ubiquitin specific protease 18 (USP18) negatively regulates interferon signaling in cancer cells and tests whether blocking USP18-mediated suppression of the interferon response can enhance the...
- The National Institutes of Health National Cancer Institute awarded the University of California, San Diego $771,811 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify small molecule activators of type I interferon signaling for cancer treatment. The research focuses on discovering and developing small molecule inhibitors targeting USP18, a ubiquitin protease that suppresses the type I interferon response through negative feedback regulation. Prior work...
- The National Cancer Institute awarded the University of California Irvine $807,372 on March 19, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a genetic screening approach identifying and exploiting drug-diet interactions that enhance cancer therapy efficacy. The research establishes a parallel screening platform using syngeneic orthotopic pancreatic ductal adenocarcinoma models to evaluate interactions between over 2,000 drug targets and defined dietary interventions...
- The National Institutes of Health National Cancer Institute awarded the University of California, San Diego $661,721 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to conduct systematic functional mapping and interrogation of oncogenic intrinsically disordered regions in cancer driver proteins. The research employs high-throughput functional screening technologies and computational frameworks to systematically map intrinsically disordered regions across approximately...
- The National Cancer Institute awarded the University of California, Los Angeles $528,265 on May 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct fragment-based drug discovery against oncogenic microRNA precursors using high-throughput crystallography. The funded research targets the precursor structures (pre-miRNAs) of oncogenic microRNAs (oncomirs) that fold into hairpin configurations recognized and cleaved by microRNA processing enzymes. The project performs...
- The National Cancer Institute awarded the University of California Irvine $125,294 on September 20, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support development of a methyl arginine targeting chimera for lysosomal degradation of intracellular proteins. The project addresses limitations of current targeted-protein degradation approaches. Existing proteolysis-targeting chimeras (PROTACs) degrade disease-causing proteins through proteasomal pathways but face capacity...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $640,466 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop covalent protein radiopharmaceuticals for targeted radionuclide therapy in cancer treatment. The project, funded through a Project Grant (R01CA309883), addresses a fundamental challenge in radiopharmaceutical design: balancing tumor uptake efficacy with safety by minimizing radiation exposure to normal...
- The National Institutes of Health National Cancer Institute awarded the University of Southern California $479,234 on May 15, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate nonsense-mediated mRNA decay mechanisms in cancer biology. The project explores how nonsense-mediated mRNA decay (NMD) functions beyond its conventional role of degrading faulty transcripts, with three specific aims: decode gene dependencies in cancer cell lines using NMD residual signatures from...
- The National Institutes of Health National Cancer Institute awarded the University of North Carolina at Chapel Hill $653,846 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop targeted protein degradation therapeutics that hijack the FBXO22 E3 ubiquitin ligase for cancer treatment. The project, titled "Hijacking FBXO22 for the Development of Novel Cancer Therapeutics," advances targeted protein degradation as an emerging therapeutic strategy that...
- The National Cancer Institute awarded The Broad Institute, Inc. $651,409 under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2026, to probe cereblon allostery with small molecules as a novel approach to targeted protein degradation for cancer therapy. The research examines how allosteric binding at a newly discovered site on cereblon—an E3 ligase substrate adapter targeted by thalidomide derivatives—can modulate protein recruitment and degradation independently or...